# Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

> **NCT06439485** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Advanced Cholangiocarcinoma
- FGFR2 Fusion

## Interventions

- **DRUG:** Pemigatinib
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06439485
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2028-02-22
- **Final completion:** 2030-02-22
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439485, "Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06439485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*